Description

A clopidogrel response (CYP2C19) genotype test determines how well someone metabolizes clopidogrel, a drug used to prevent blood clots. The test identifies genetic variations in the CYP2C19 gene. 

What does the test result mean? 

  • Poor metabolizers (PM)
  • People with two loss-of-function copies of the CYP2C19 gene. PMs have reduced enzyme activity and cannot activate clopidogrel.
  • Intermediate metabolizers (IM)
  • People with one loss-of-function copy of the CYP2C19 gene. IMs may have one normal function copy or one increased function copy.

What does this mean for treatment? 

  • People with CYP2C19 genetic variations who take clopidogrel may not get the full benefit of the drug.
  • They may be at higher risk of having a heart attack or stroke.
  • Healthcare providers can use the results to decide on the right antiplatelet treatment.

Other information

  • The most common loss-of-function alleles are CYP2C192 and CYP2C193. 
  • Platelet function tests can also help guide antiplatelet therapy.

 Test takes 14 business days not including transportation time.